SG11201807574XA - Beta-caseins and cognitive function - Google Patents

Beta-caseins and cognitive function

Info

Publication number
SG11201807574XA
SG11201807574XA SG11201807574XA SG11201807574XA SG11201807574XA SG 11201807574X A SG11201807574X A SG 11201807574XA SG 11201807574X A SG11201807574X A SG 11201807574XA SG 11201807574X A SG11201807574X A SG 11201807574XA SG 11201807574X A SG11201807574X A SG 11201807574XA
Authority
SG
Singapore
Prior art keywords
beta
international
casein
pct
milk
Prior art date
Application number
SG11201807574XA
Inventor
Andrew John Clarke
Gregory Wayne Yelland
Original Assignee
A2 Milk Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=59964978&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201807574X(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by A2 Milk Co Ltd filed Critical A2 Milk Co Ltd
Publication of SG11201807574XA publication Critical patent/SG11201807574XA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/01—Hydrolysed proteins; Derivatives thereof
    • A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
    • A61K38/018—Hydrolysed proteins; Derivatives thereof from animals from milk
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
    • A23C9/1526—Amino acids; Peptides; Protein hydrolysates; Nucleic acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/20—Dietetic milk products not covered by groups A23C9/12 - A23C9/18
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/142—Amino acids; Derivatives thereof
    • A23K20/147—Polymeric derivatives, e.g. peptides or proteins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/19—Dairy proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/20—Milk; Whey; Colostrum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/322—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the nervous system or on mental function
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2250/00—Food ingredients
    • A23V2250/54—Proteins
    • A23V2250/542—Animal Protein
    • A23V2250/5424—Dairy protein
    • A23V2250/54246—Casein

Abstract

Figure100 90 80 70 g 40 20 10 SCIT Error HEAD (Automatic) TAIL (Controlled) 16 32 46 64 Exposure Duration SO 26 Conventional milk 0- A2 beia-casein only milk - Baseline conventional mak q Baseline A2 beta-casein only ink W O 20 1717 / 15 63 Al (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2017/171563 Al 5 October 2017 (05.10.2017) WIPO I PCT 111111110111101110101011111010111110111010111110111110110110011111011110111111 (51) International Patent Classification: A61K 35/20 (2006.01) A23L 33/19 (2006.01) A23C 9/20 (2006.01) A61P 25/28 (2006.01) (21) International Application Number: PCT/NZ2017/050035 (22) International Filing Date: 29 March 2017 (29.03.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/315,441 30 March 2016 (30.03.2016) (71) Applicant: THE A2 MILK COMPANY LIMITED [NZ/NZ]; C/- Simpson Grierson, Level 27, 88 Shortland Street, Auckland (NZ). (72) Inventors: CLARKE, Andrew John; 58 Gladstone Road, Parnell, 1052 Auckland (NZ). YELLAND, Gregory Wayne; 17 Corumma Court, Waveley, Victoria 3150 (AU). (74) Agent: CATALYST INTELLECTUAL PROPERTY; Level 5, 111 Customhouse Quay, 6011 Wellington (NZ). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: with international search report (Art. 21(3)) US ( 84 ) (54) Title: BETA-CASEINS AND COGNITIVE FUNCTION (57) : Improving the cognitive function of an animal by providing a composition containing beta-casein, wherein at least 75% by weight of the beta-casein is a beta-casein variant that does not produce BCM-7 on digestion in the gut of the animal.
SG11201807574XA 2016-03-30 2017-03-29 Beta-caseins and cognitive function SG11201807574XA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662315441P 2016-03-30 2016-03-30
PCT/NZ2017/050035 WO2017171563A1 (en) 2016-03-30 2017-03-29 Beta-caseins and cognitive function

Publications (1)

Publication Number Publication Date
SG11201807574XA true SG11201807574XA (en) 2018-10-30

Family

ID=59964978

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201807574XA SG11201807574XA (en) 2016-03-30 2017-03-29 Beta-caseins and cognitive function

Country Status (19)

Country Link
US (1) US11504412B2 (en)
EP (1) EP3436038B1 (en)
JP (1) JP7394527B2 (en)
KR (1) KR102471621B1 (en)
CN (1) CN109069540B (en)
AU (1) AU2017240635B2 (en)
BR (1) BR112018068817A2 (en)
CA (1) CA3017727C (en)
CL (1) CL2018002688A1 (en)
ES (1) ES2886647T3 (en)
IL (1) IL261704B (en)
MX (1) MX2018011817A (en)
MY (1) MY193655A (en)
NZ (1) NZ746167A (en)
PH (1) PH12018550149A1 (en)
RU (1) RU2766194C2 (en)
SG (1) SG11201807574XA (en)
WO (1) WO2017171563A1 (en)
ZA (1) ZA201806247B (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017171563A1 (en) 2016-03-30 2017-10-05 The A2 Milk Company Limited Beta-caseins and cognitive function
CN114586983A (en) * 2022-03-07 2022-06-07 黑龙江飞鹤乳业有限公司 Nutritional composition for promoting neural development and preparation and application thereof
CN114716531B (en) * 2022-05-17 2023-11-03 中国农业科学院农业质量标准与检测技术研究所 Casein polypeptide, polypeptide antigen, antibody, test strip and application thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0789842B1 (en) * 1994-11-04 2009-09-09 A2 Corporation Limited Method of selecting non-diabetogenic milk or milk products and milk or milk products so selected
ATE297125T1 (en) 1995-05-16 2005-06-15 A2 Corp Ltd FOODS AND PRODUCTION PROCESSES
RU2161500C1 (en) 1999-07-06 2001-01-10 Институт молекулярной генетики РАН Heptapeptide with adaptogenic and anxiolytic activity
WO2002019832A1 (en) * 2000-09-08 2002-03-14 New Zealand Dairy Board MILK CONTAINING β-CASEIN WITH PROLINE AT POSITION 67 DOES NOT AGGRAVATE NEUROLOGICAL DISORDERS
WO2007079977A2 (en) * 2006-01-16 2007-07-19 Dsm Ip Assets B.V. Nutraceutical compositions comprising tripeptides
EP2422629A1 (en) 2010-08-23 2012-02-29 Abbott Laboratories Methods for enhancing cognition and/or memory using maltodextrins
BR112015029987A2 (en) 2013-05-31 2017-07-25 A2 Milk Co Ltd beta casein a2 and the prevention of bowel inflammation
BR112016000612B8 (en) 2013-07-12 2022-02-22 A2 Milk Co Ltd Use of milk in the manufacture of a composition to prevent or reduce symptoms of lactose intolerance
ES2899732T3 (en) 2013-08-23 2022-03-14 A2 Milk Co Ltd Betacasein A2 and blood glucose levels
WO2015187795A1 (en) * 2014-06-03 2015-12-10 Abbott Laboratories Nutritional compositions comprising a lipophilic active ingredient
JP6005202B2 (en) * 2015-03-19 2016-10-12 アサヒグループホールディングス株式会社 Enzymatic production of peptide for improving brain function
BR112017024975B1 (en) * 2015-05-22 2022-03-15 The A2 Milk Company Limited Use of bovine milk containing beta-casein
CN105053217A (en) * 2015-09-14 2015-11-18 海普诺凯营养品有限公司 Infant formula ewe milk powder and production method thereof
CA3009360A1 (en) 2015-12-22 2017-06-29 The A2 Milk Company Limited Infant formula comprising human milk peptides
WO2017171563A1 (en) 2016-03-30 2017-10-05 The A2 Milk Company Limited Beta-caseins and cognitive function

Also Published As

Publication number Publication date
RU2766194C2 (en) 2022-02-09
MX2018011817A (en) 2019-01-24
RU2018132691A (en) 2020-04-30
CA3017727C (en) 2024-03-12
JP2019509755A (en) 2019-04-11
CN109069540B (en) 2023-03-28
AU2017240635A1 (en) 2018-10-04
WO2017171563A1 (en) 2017-10-05
US11504412B2 (en) 2022-11-22
ES2886647T3 (en) 2021-12-20
ZA201806247B (en) 2019-06-26
BR112018068817A2 (en) 2019-01-22
NZ746167A (en) 2023-04-28
KR102471621B1 (en) 2022-11-25
MY193655A (en) 2022-10-23
CN109069540A (en) 2018-12-21
RU2018132691A3 (en) 2020-06-25
IL261704B (en) 2022-04-01
EP3436038A1 (en) 2019-02-06
CL2018002688A1 (en) 2019-01-18
AU2017240635B2 (en) 2023-01-19
KR20180129829A (en) 2018-12-05
PH12018550149A1 (en) 2019-03-25
TW201737936A (en) 2017-11-01
IL261704A (en) 2018-10-31
US20190083567A1 (en) 2019-03-21
CA3017727A1 (en) 2017-10-05
JP7394527B2 (en) 2023-12-08
EP3436038B1 (en) 2021-06-23
EP3436038A4 (en) 2019-11-20

Similar Documents

Publication Publication Date Title
SG11201903882VA (en) Il-2 variants for the treatment of autoimmune diseases
SG11201810602YA (en) Method of treating liver fibrosis
SG11201805470VA (en) Code and container of system for preparing a beverage or foodstuff
SG11201909963YA (en) Methods for treating dravet syndrome
SG11201805828YA (en) Method of treating c3 glomerulopathy
SG11201908971RA (en) Erbb-2 and erbb3 binding bispecific antibodies for use in the treatment f cells that have an nrg1 fusion gene
SG11201805709RA (en) Anti-pro/latent myostatin antibodies and methods of use thereof
SG11201805072PA (en) Nicotine powder delivery system
SG11201810757YA (en) Non-human animals expressing exogenous terminal deoxynucleotidyltransferase
SG11201807827VA (en) Process for the preparation of pegylated drug-linkers and intermediates thereof
SG11201902531QA (en) Liquid pharmaceutical composition
SG11201806544XA (en) Compounds and methods of treating rna-mediated diseases
SG11201809527UA (en) Methods of treating circadian rhythm sleep disorders
SG11201806432PA (en) Methods for assessing risk of developing colorectal cancer
SG11201804587QA (en) Isoindole compounds
SG11201804821PA (en) A beverage capsule
SG11201808525UA (en) Anti-complement factor bb antibodies and uses thereof
SG11201805001UA (en) Method of treating influenza a
SG11201909003YA (en) Integrated vascular access device and anchor pad
SG11201903193WA (en) Deodorant comprisng a zinc carboxylate salt and aluminium chlorohydrate
SG11201908513RA (en) Peptides for treatment of diabetes
SG11201807516UA (en) 5-ethyl-4-methyl-pyrazole-3-carboxamide derivative having activity as agonist of taar
SG11201810940XA (en) Methods of treating pancreatic cancer
SG11201906778RA (en) Improved methods for assessing risk of developing breast cancer
SG11201807283XA (en) Rider-controlled trackless ride system